WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Domain Name Industry Friday, February 23, 2018 
Add Press Release News | News Feeds Feeds | Email This News Email

CRISPR - Fast Initial Growth, But Long-Term Revenues Will Depend on "Wins"
Tuesday, February 13, 2018

ROCKVILLE, Md., Feb. 13, 2018 /PRNewswire/ -- New York City-based market research firm Kalorama Information projects fast revenue growth for the most important gene editing technology CRISPR/Cas9 - 33.7% growth over the next five years, as revenues grow from $779 million in 2017 to $5.2 billion in 2023.

But Kalorama said the technology revenue growth will slow during that period from its current breakneck pace, and novelty growth will be proved in the marketplace by winning applications. The finding was made in Kalorama Information's report: The Market and Potential for CRISPR/Cas9 Gene Editing.

"It's a technology that can be used for a broad group of applications - drugs to food to disease research," said Bruce Carlson, Publisher of Kalorama Information. "A lot of customers is always a good sign for a market. That being said, growth is not without limits and we will watch over the next five years how many wins the technology can score in real-world applications"

The CRISPR-Cas9 gene editing systems consist of a short, non-coding RNA molecule as the DNA binding domain, and a Cas9 enzyme having DNA-cleaving function. The RNA molecule also has the role of guiding the Cas9 enzyme to the targeted genomic location, which is typically 20 nucleotides in length. Cas9 is the protein that makes gene-editing work. Basically, Cas9 helps to snip out a piece of DNA at any point in an organism--including, for instance, viral or faulty DNA--and then enables the cell to stitch the ends back together.

CRISPR screening is being applied to numerous aspects of functional genomics, including transcription factors, non-coding RNAs and protein-protein interactions, especially in cancer cells. Kalorama Information said to watch for developments in biodrugs or other areas as a result of CRISPR/Cas9 for an indication of whether brisk investments will continue.

The report said market will be a larger factor in North America and Europe, with over 70% of revenues, but other markets will demonstrate faster revenue growth for a longer period. Agilent, GE Healthcare, Thermo Fischer, Gene Script, CRISPR Therapeutics and Precision Biosciences are leaders in the market.

Developments in CRISPR, market projections and forecasts, and company partnership information is covered in Kalorama Information's report. Kalorama also covers markets for biotech instrumentation, next-generation sequencing, molecular testing systems and reagents, biosimilar drugs and several other recent topics in large market research studies. The companies biotechnology reports can be found at:

About Kalorama Information

Kalorama Information, a division of, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on and

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.

Press Contact:
Bruce Carlson
212 807 2262

View original content with multimedia:

SOURCE Kalorama Information

Email This News Email | Submit To Slashdot Slashdot | Submit To Digg | Submit To | News Feeds Feeds

Nav CEVA and mPerpetuo Partner to Deliver Halide Support for CEVA Vision Processors | Feb 23, 2018
Nav Defence IQ Launch: Land ISR & C2 Battle Management 2018 | Feb 23, 2018
Nav Hitachi Consulting Selected to Design 'Smart City' Services For One Bangkok, Thailand's Largest Private Sector Property Project | Feb 22, 2018
Nav China Mobile Leads in Telco Innovation for 5G While European Telcos Merely Spectate | Feb 22, 2018
Nav Global Mobile Payment Market Expected to Reach $ 4,574 Billion by 2023 - Allied Market Research | Feb 22, 2018
Nav Codewise appoints John Malatesta as Chief Revenue and Marketing Officer and Excom Member | Feb 21, 2018
Nav DomainTools Launches Innovative Predictive Domain Risk Scoring Model | Feb 21, 2018
Nav Global Blinds and Shades Industry | Feb 21, 2018
Nav SRC Technologies Debuts Security Awareness Training Service, Helps Wisconsin Business Leaders Prevent Phishing Scams | Feb 21, 2018
Nav Engility announces CyberWarrior┬« Scholarship recipients | Feb 21, 2018

Submit News | View More News View More News